Arnoud H. J. Herremans

Synthesis, Biological Properties, and Molecular Modeling Investigations of Novel 3,4-Diarylpyrazolines as Potent and Selective CB₁ Cannabinoid Receptor Antagonists

Jos H.M. Lange, Hein K. A. C. Coolen, Herman H. van Stuivenberg et al. · Journal of Medicinal Chemistry · 2003 · 188 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Behavioural changes after different stress paradigms: prepulse inhibition increased after physical, but not emotional stress

Femke Buisman‐Pijlman, Arnoud H. J. Herremans, Jan van de Kieft et al. · European Neuropsychopharmacology · 2003 · 67 citations

Nursing, Neuroscience, Psychology +15

Effects of infusion of cholinergic drugs into the prefrontal cortex area on delayed matching to position performance in the rat

Arnoud H. J. Herremans, Theo H. Hijzen, Patrick F.E. Welborn et al. · Brain Research · 1996 · 64 citations

Life Sciences, Neuroscience, Pharmacology +17

SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug

Andrew C. McCreary, Jeffrey Glennon, Charles R. Ashby et al. · Neuropsychopharmacology · 2006 · 58 citations

Medicine, Neuroscience, Pharmacology +14

Synthesis, Structure−Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[ω-(1<i>H</i>-indol-3-yl)alkyl]piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D₂ Receptor Antagonism with Potent Serotonin Reuptake Inhibition

Pieter Smid, Hein K. A. C. Coolen, Hiskias G. Keizer et al. · Journal of Medicinal Chemistry · 2005 · 58 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16